Journal
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
Volume 37, Issue 6, Pages 1636-1642Publisher
SPANDIDOS PUBL LTD
DOI: 10.3892/ijmm.2016.2569
Keywords
laryngeal carcinoma; microRNA; chemotherapy; copper transporting P-type adenosine triphosphatase
Categories
Funding
- Jilin Province Technique-Development Plan [200905197]
- Jilin Province Health Development [2009Z021]
Ask authors/readers for more resources
The expression levels of the copper transporter P-type adenosine triphosphatase (ATP7B) are known correlate with tumor cell sensitivity to cisplatin. However, the mechanisms underlying cisplatin resistance remained poorly understood. Therefore, in the present study, we treated Hep-2 cells and in-house-developed vincristine-resistant Hep-2v cells with 50, 100, or 200 mu M cisplatin and assessed cell viability after 24 or 48 h. Hep-2v cells were shown to be resistant to 50-200 mu M cisplatin. Furthermore, using immunofluorescence staining and western blot analysis, we noted that ATP7B, but not copper-transporting ATPase 1 (ATP7A), expression was significantly increased in Hep-2v cells, and this increase was maintained at a higher level compared with Hep-2 cells. As ATP7B is a target of microRNA 133a (miR-133a), the ability of miR-133a to influence cisplatin sensitivity in Hep-2v cells was then assessed by CCK-8 assay. We noted that miR-133a expression was lower in both Hep-2 and Hep-2v cells compared with epithelial NP69 cells. Following treatment with 50 mu M cisplatin, in Hep-2v cells expressing exogenous miR-133a we noted reduced ATP7B expression, and these cells had a significantly lower survival rate compared with the control. The present study demonstrates that miR-133a enhances the sensitivity of multidrug-resistant Hep-2v cells to cisplatin by downregulating ATP7B expression.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available